High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: Using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 2, 2011, Pages 246-252

  Shields, Ryan K ^a   Kwak, Eun J ^a   Potoski, Brian A ^a   Doi, Yohei ^a   Adams Haduch, Jennifer M ^a   Silviera, Fernanda P ^a   Toyoda, Yoshiya ^a   Pilewski, Joseph M ^a   Crespo, Maria ^a   Pasculle, A William ^a   Clancy, Cornelius J ^a,b   Nguyen, M Hong ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VA Pittsburgh Healthcare System   (United States)

Author keywords

Acinetobacter; Colistin; Doripenem; Synergy; Transplant

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; COLISTIN; DORIPENEM; IMIPENEM; MEROPENEM; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CONTROLLED STUDY; EMPYEMA; FEMALE; HEART TRANSPLANTATION; HUMAN; IN VITRO STUDY; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MEDIASTINITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MIDDLE AGED; ORGAN TRANSPLANTATION; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 79955963693     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.12.023     Document Type: Article

References (26)

1. Aaron S.D. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr. Respir. Rev. 2007, 8:256-261.
2. Adams-Haduch J.M., Paterson D.L., Sidjabat H.E., Pasculle A.W., Potoski B.A., Muto C.A., Harrison L.H., Doi Y. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob. Agents Chemother. 2008, 52:3837-3843.
3. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48:1-12.
4. Doi Y., Husain S., Potoski B.A., McCurry K.R., Paterson D.L. Extensively drug-resistant Acinetobacter baumannii. Emerg. Infect. Dis. 2009, 15:980-982.
5. Freire A.T., Melnyk V., Kim M.J., Datsenko O., Dzyublik O., Glumcher F., Chuang Y.C., Maroko R.T., Dukart G., Cooper C.A., Korth-Bradley J.M., Dartois N., Gandjini H. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 2010, 68:140-151.
6. Gales A.C., Jones R.N., Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of Gram-negative bacilli: a report from SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect. 2006, 12:315-321.
7. Giamarellos-Bourboulis E.J., Xirouchaki E., Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 2001, 40:117-120.
8. Haddad F.A., VanHorn K., Carbonaro C., Aguero-Rosenfeld M., Wormser G.P. Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24:577-579.
9. Hawley J.S., Murray C.K., Jorgensen J.H. Colisting heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 2008, 52:351-352.
10. Korbila I.P., Michalopoulos A., Rafailidis P.I., Nikita D., Samonis G., Falagas M.E. Inhaled colistin as adjunctive to intravenous colistin for the treatment of microbiologically documented VAP: a comparative cohort study. Clin. Microbiol. Infect. 2009, [Epub ahead of print].
11. Landman D., Butnariu M., Bratu S., Quale J. Genetic relatedness of multidrug-resistant Acinetobacter baumannii endemic in New York City. Epidemiol. Infect. 2009, 137:174-180.
12. Lee Y., Yum J.H., Kim C.K., Yong D., Jeon E.H., Jeong S.H., Ahn J.Y., Lee K. Role of OXA-23 and AdeABC efflux pump for acquiring carbapenem resistance in an Acinetobacter baumannii strain carrying the blaOXA-66 gene. Ann. Clin. Lab. Sci. 2010, 40:43-48.
13. Lolans K., Rice T.W., Munoz-Price L.S., Quinn J.P. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob. Agents Chemother. 2006, 50:2941-2945.
14. Mak J.K., Kim M., Pham J., Tapsall J., White P.A. Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 2009, 63:47-54.
15. Motaouakkil S., Charra B., Hachimi A., Nejmi H., Benslama A., Elmdaghri N., Belabbes H., Benbachir M. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infection. 2006, 53:274-278.
16. Pankey G.A., Ashcraft D.S. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn. Microbiol. Infect. Dis. 2009, 63:228-232.
17. Paterson D.L., Rogers B.A. How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrug-resistant bacterial infection. Clin. Infect. Dis. 2010, 51:1245-1247.
18. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., Husain S., Kwak E.J., Bhat S.V., Paterson D.L. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother. 2007, 59:128-131.
19. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2007, 51:3471-3484.
20. Pillai S.K., Moellering R.C., Eliopoulos G.M. Antimicrobial combinations. Antibiotics in laboratory medicine 2005, Lippincott Williams and Wilkins., Philadelphia, PA. 5th ed. V. Lorian (Ed.).
21. Savini V., Catavitello C., Pompetti F., Talia M., Costanzi L., Balbinot A., Febbo F., Di Zacomo S., Esattore F., D'Antonio D. Isolation of uncommon respiratory and enteric Acinetobacter baumannii from hematologic patients and emergence of tigecycline-resistance. J. Infect. 2008, 57:497-500.
22. Schafer J.J., Goff D.A., Stevenson K.B., Mangino J.E. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007, 27:980-987.
23. Song J.Y., Lee J., Heo J.Y., Noh J.Y., Kim W.J., Cheong H.J. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 2008, 32:278-286.
24. Sopirala M.M., Mangino J.E., Gebreyes W.A., Biller B., Bannerman T., Balada-Llasat J.M., Pancholi P. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2010, 54:4678-4683.
25. Souli M., Galani I., Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro. Surveill. 2008, 13.
26. Urban C., Mariano N., Rahal J.J. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother. 2010, 54:2732-2734.